SEF Chemo: Broad Spectrum Chemo-Immunotherapy That Treats Most Cancers with Minimal Side Effects


Medicor Cancer Centres is privileged to be the third center in the world to receive authorization to administer a unique therapy called “Side Effect-Free” or SEF chemo (pronounced “safe” chemo)SM. This treatment was developed by Dr. Ken Matsumura (of Berkeley, California) and his team of researchers. Dr. Matsumura is a physician and the inventor of the world’s first artificial liver, artificial pancreas and wrist watch heart alarm:,28804,1936165_1936238_1936293,00.html

Many researchers around the world are trying to develop drugs which target cancer cells while sparing healthy cells in the body from injury. This has largely been a failure. Dr. Matsumura selected the opposite approach: use a powerful chemotherapy drug that aggressively kills cancer cells but also damages some healthy cells, combined with an antidote to protect the healthy cells in the body. It took over 30 years of research to develop this new therapy, and we have received permission to use it since mid-2013, with the ongoing guidance of the Berkeley Institute’s SEF chemo team.


Although it is called “side effect free”, there is no such thing as any drug therapy with zero side effects. In reality, many patients experience so few side effects that they would not feel like they are receiving chemotherapy at all. For example, typically there is no hair loss or vomiting, and the most common side effects are mild to moderate fatigue and mild nausea for 3 or 4 days after treatment, despite minimal anti-nausea drugs use (no steroid). Most patients experience stable or mildly reduced blood cell counts, without immune suppression. It is also common to have pain in the areas of tumours, due to inflammation that occurs as the cancer cells are being attacked by the immune system.


The standard drugs used for SEF chemotherapy are carboplatin with mesna as an antidote. Both of these drugs are generic and legally can be used for cancer therapy in Canada. Since they are only approved for a small number of cancer types in Canada, in most cases they are being prescribed “off label”, in other words, not for their “approved” purpose. Off-label drug therapy is legal in Canada and is permitted by the College of Physicians and Surgeons of Ontario.

Occasionally a second gentler chemo drug may be added to enhance the carboplatin (if the cancer responds slowly to carboplatin alone). This may consist of gemcitabine or capecitabine. We prefer to avoid adding a second chemo, since this chemo drug is not being used with an antidote. More often we are combining intravenous sodium phenylbutyrate or metformin with SEF chemo since our lab research and patient data indicate these drugs can be powerful chemosensitizers. That means these drugs can allow the chemo to work much better, but without creating immune suppression or other serious side effects.


Dr. Matsumura has reported approximately 90% response rate for patients with stage 3 and early stage 4 cancers, and in the first small clinical trial of 6 patients, 4 achieved a long-term complete remission of cancer (no detectable cancer in the body for years after therapy).

For our first 20 patients (almost all stage 4 cancers, various types including rare tumours and those that typically respond poorly to chemo), our overall response rate was over 80% using modified RECIST definitions. After some adjustments to the therapy to account for the unique patient population we serve, our response rate has increased to over 90%. This type of response rate is 2 to 5 times higher than conventional approved chemotherapy in these types of patients. Since the data is preliminary (small patient numbers), direct comparison to published chemo response rates, as determined by large clinical trials, is not entirely fair. However, the SEF chemo responses indicate the therapy is very promising.

Complete remission is possible, especially for patients with low disease bulk (even if they are stage 4). For example, one of our early SEF patients with stage 4 cervical cancer spread to the abdomen and lungs achieved complete remission as determined by clear scans, normal tumour markers, circulating tumour cell count of 0, and repeat circulating tumour cell count of 0, performed 3 months after therapy completion. She received no conventional cancer therapy along with SEF chemo.

Near-remission is possible for patients with larger amount of disease. This can increase the chance of response to non-toxic drugs after completion of SEF chemo, which allows us to achieve long-term cancer stability and prolonged survival.

Despite the initial promising results, SEF chemo is not accepted by Cancer Care Ontario, the College of Physicians and Surgeons of Ontario, or large cancer hospitals. SEF chemo is considered to be a complementary/alternative cancer therapy.




We often hear comments from patients or oncologists asking how such good responses are possible, when standard chemo responses seem to be relatively poor. The key to the improving response to chemo is protection of the bone marrow from damage by the chemo. If the bone marrow is protected, the white cells are not compromised, and they participate in the killing of cancer cells. In other words, this is not just “chemotherapy”, rather it is “chemo-immunotherapy”, with the patient’s own immune system contributing a large percentage of cancer cell kill.

Most oncologists have never used any therapy that is similar to SEF chemo, and therefore are not in a good position to make adverse judgments against this therapy. If your oncologist expresses concern, we recommend you ask them if they are familiar with the concept of using antidotes which prevent chemo side effects, but do not interfere with chemo effectiveness. An example is the use of folinic acid to prevent side effects of methotrexate chemo. If they are familiar with this concept, they should at least recognize the possibility that SEF chemo is based on sound science and may work as claimed.

Your oncologist may feel that the lack of published data on SEF chemo means it cannot be real. They would be partly correct – the data remains unpublished. However, publication does not determine if a therapy is real or not. Dr. Matsumura has made the decision to withhold publication of his clinical trial, for a number of reasons which are too long to discuss here. The United States FDA gave approval to begin his first clinical trial after a record review time of just 4 days. We were given permission to review Dr. Matsumura’s internal patient data, and we were satisfied that the therapy was real. In addition, after using it for over 3 years, we can state clearly that it works as intended. It is not a simple therapy, but when it is done correctly in the right patients, it can work quickly and safely, and give amazing results.


We are seeing strong responses with non-small cell lung cancer, small cell lung cancer, breast cancer (including triple negative/chemo-resistant), melanoma, pancreatic cancer, non-Hodgkin’s lymphoma, ovarian cancer, cervical cancer, liposarcoma, and prostate cancer. Since carboplatin is a “broad-spectrum” chemo drug, and SEF chemo creates an immune response against the cancer, it is possible that any cancer type will respond well, including rare tumours and unknown primary tumours.

Dr. Matsumura has reported cures of leukemia with a small number cycles of SEF chemo. We have not yet had the opportunity to treat leukemia with this therapy, but we are excited to offer it to interested leukemia patients who meet certain criteria.

For the first time in the world, SEF chemo has been used successfully with glioblastoma. Previously, SEF was not used at all with brain tumours due to the risk of sudden life-threatening brain swelling. Based on our experience in Toronto, we have received permission from Dr. Matsumura to continue to use SEF chemo in selected patients with glioblastoma, who have minimal disease volume (small tumours, or no visible tumour after surgery).


The standard treatment schedule consists of 4 days of intravenous treatment, given on a 2 week cycle:

On day #1, a mesna infusion will be given.
On day #2, a mesna infusion is given followed by an infusion of carboplatin chemo after about 3 hours.
On day #3, a mesna infusion is given.
On day #4, a final mesna infusion is given.

For further details, please see SEF Chemo Patient Instructions

After 3 cycles of therapy, patients are assessed to determine if they are responding well. If so, then the therapy is continued until the cancer is in remission, or until there is therapy failure, or until there are side effects or other reasons that cause the patient to stop. We estimate that a remission of stage 3 or early stage 4 cancers will require 10-15 cycles of “safe” chemo, depending on the speed of response. If therapy continues to work but the cancer is not in remission by 12-15 cycles, we generally recommend switching to another therapy.

In Toronto, the carboplatin dose for the standard SEF protocol is about 80% of what is given in hospitals, but it is given about 1.5 – 2 times as often. This means patients receive more chemo than standard hospital protocols, yet they experience far fewer side effects.


In 2016 we have started using a new SEF chemo regimen developed by Dr. Matsumura to help patients with compromised bone marrow and low cell counts (mainly due to prior toxic chemo use). This regimen is also gentler and is thus useful for advanced cases where very rapid killing of the cancer cells would cause complications. It consists of a low chemo dose, with 3 days of intravenous treatment, given on a 1 week cycle:

On day #1, a mesna infusion is given.
On day #2, a mesna infusion is given followed by an infusion of carboplatin chemo after about 3 hours.
On day #3, a mesna infusion is given.

For further details, please see SEF Chemo Patient Instructions

After 6 cycles of low dose weekly therapy, patients are assessed to determine if they are responding well.

The carboplatin dose for the low dose SEF protocol is about 30% of what is given in hospitals, but it is given about 3 – 4 times as often. This means patients receive about the same total chemo per month as in standard hospital protocols, yet they experience far fewer side effects.


Routine weekly blood tests will be performed. Routine urine tests are performed only as needed. Tumour markers may be tested every 1-2 months (these do not apply to all patients). Tumour markers may show sudden increases with SEF chemo, even with the therapy is effective. Routine imaging tests will be performed to monitor the cancer (such as x-rays, ultrasounds with Doppler to measure a tumour’s blood flow, MRI, CT and PET/CT scans). The exact imaging required will depend on the patient’s unique situation. Maintrac live cell circulating tumour cell testing will be performed in most cases (blood samples are sent to a specialized lab in Germany). This test can be used to monitor patients who have no tumours visible on any scan, but are not cancer-free. Maintrac cannot be used for leukemia or lymphoma.

For SEF chemotherapy, CT or PET scans can falsely suggest tumour growth if done at the wrong time. This is related to inflammation and swelling in the tumours caused by the immune system attacking the cancer rapidly. We are aware of this issue, and will order the most appropriate scans with the correct timing, and will help interpret the results for you. We do not rely on any one test alone to interpret the response to treatment. Please note that a CT scan is NOT the “gold standard” to assess the cancer’s response to therapy when a patient is treated with SEF chemo.




Most of our patients have received natural medicines at some point as part of their cancer therapy. While we understand that interactions between natural medicines and carboplatin chemo may be favourable (like mistletoe or IV vitamin C), we do not have adequate data for interaction of natural medicines with carboplatin + mesna. We have already witnessed a few negative interactions which resulted in treatment failure. Since Dr. Matsumura has achieved remarkable results of SEF chemo without the use of supplements, we ask all SEF chemo patients to hold their supplements beginning 1 week prior to the therapy start. Natural therapies may resume after SEF chemo completion. For patients who find it difficult to avoid supplements, please keep in mind that mesna is like a “mega supplement” because it provides a high degree of protection against the chemo toxicity.

Natural medicines that are not absorbed into the bloodstream are permitted (e.g. oral probiotic or some skin creams). Essential oils are NOT permitted (oral and topical). Natural medicines which enhance blood cell counts are NOT permitted (like mistletoe). Enemas with natural medicines or coffee are NOT permitted. Vitamin D is permitted and encouraged since we have tried combining high dose vitamin D with SEF chemo, and not seen any issues. Please check with Dr. Khan for further advice. After completion of SEF chemo, it is important to return to your naturopathic doctor for ongoing cancer prevention advice.


Some physicians have expressed concern about our administration of chemotherapy drugs outside of a hospital setting. This is currently permitted, although the guidelines and safety standards that must be followed are very strict. Medicor has obtained and reviewed many chemotherapy guidelines from Ontario, B.C., Québec, and USA. Best practices have been taken from these guidelines to create a comprehensive set of standards that is most suitable for our SEF chemo program. These standards can be found in the Medicor Safe Chemo Policy and Procedure Manual. If desired, the manual is available for viewing in person in the office, by making a written request to the Medicor C.E.O. In addition we have been subjected to a surprise audit of the entire SEF chemo program by the provincial physician regulatory body, with no adverse findings to date. We are also constantly working to improve our standards of care delivery from year to year. It is our hope to always meet or exceed all applicable safety standards of chemo administration.


Medicor does not sell SEF chemo, we only infuse it. We do not set the price, this is determined by the Berkeley Institute. Payment for SEF chemo must be made directly to the Berkeley Institute with a credit card. Payment is made with each cycle of therapy, just 1 day before therapy begins (pre-payment for multiple cycles is not required). The cost of SEF chemo (including carboplatin + mesna) is roughly $4000 US per 2 week cycle. There is an additional one-time consultation fee of approximately $600 for the Berkeley Team at the start of therapy. There will be additional charges if a second chemo drug (gemcitabine) is needed, although we rarely use this drug in Toronto. Patients should budget for 3 cycles to try the therapy and determine how their cancer responds. If there is a favourable response, patients should budget for an additional 7-12 cycles. If this is not within your budget, a different therapy should be considered. Low dose weekly SEF chemo is currently subsidized by donations from the ALIN Foundation, resulting in a total monthly cost that is close to the cost of the bi-weekly SEF chemo (currently $2300 per weekly cycle).

Québec patients must pay physician fees in addition, and can request reimbursement from le Ministère de la Santé (because there is no agreement between Québec and Ontario for government payment of physician fees). Most blood and imaging tests are covered by government insurance.

Canadian patients with a valid Health Card receive most imaging and blood tests and doctor visits at no charge. Patients with no Canadian healthcare coverage must pay physician fees and blood/imaging test fees.

Circulating tumour cell counts are not covered by government insurance (less than $600 per test). PET/CT is about $2300 per test, but is usually not required. There are additional charges for chemosensitizing drugs (if needed). We use intravenous sodium dichloroacetate, metformin and sodium phenylbutyrate as non-toxic chemosensitizers. These types of medications can enhance cancer cell kill, with minimal or no increase in side effects. Patients who have been treated previously with several chemos may have carboplatin resistance, requiring the addition of one of these drugs to achieve good results.

Private medical insurance may not cover SEF chemo in Canada. Please check with your insurance company. The Berkeley Institute does not accept direct payment from insurance. Our experience is that off-label chemo may not be covered by Canadian private insurance plans, unless prescribed by a Canadian oncologist. Therapy for our SEF chemo patients is prescribed by the Berkeley Institute team. Critical Illness Insurance and Health Spending Accounts should cover SEF chemo. Life insurance may allow advance payment of a lump sum for patients diagnosed with a life-threatening illness like cancer. Finally, you may contact a medical financing company such as Medicard or CreditMedical for quick financing with a monthly repayment plan. Medicor is registered with both companies.


Chemosensitivity / chemoresistance (CS/CR) testing is available to determine who will respond well to SEF chemo, to save the cost of trying it. Since the response rate to SEF chemo (without testing) is quite high, such testing is not necessarily required. CS/CR testing can help give you optimal results. CS/CR testing can give you an idea if you are likely to respond very quickly, and can suggest if a second drug should be combined with carboplatin from the beginning for the best response.

If you are having cancer surgery soon, you may request a small piece of live tumour (e.g. 1cm diameter) taken during surgery to be shipped fresh to a lab in USA such as AccuTheranostics (for ChemoFit test), Weisenthal Cancer Group (for Personalized Chemo test), or other high quality lab that does live cell chemosensitivity testing. These labs can test most solid tumours. The ideal time to do this type of CS/CR testing is at the time of cancer surgery. Needle biopsies likely will not obtain enough cancer cells to run tests at these labs. Open biopsies of cancers close to the skin surface, or superficial lymph nodes involved with cancer, are minimally invasive, and should yield enough cells for successful testing.

If you are not having surgery, and there is no easily accessible tumour for biopsy, we generally do not recommend an invasive biopsy just for CS/CR testing. However, it may be possible to perform a CS/CR test on live tumour cells collected from a blood sample. This is called the Maintrac CS/CR Test and is conducted through Pachmann Labs in Germany. The Maintrac chemosensitivity test is designed to work for carcinomas, but it does also work for sarcomas and other solid tumours based on our experience. Myeloma, lymphoma and leukemia cannot be tested at this lab.

The cost of CS/CR testing ranges from about $2,600US to $10,000US depending on the lab and the number of drugs tested. AccuTheranostics charges about $2600 for testing a panel of several drugs or combinations. Maintrac CS/CR testing is about $4000 for a typical set of SEF chemo drugs, although the cost can be reduced if fewer drug combinations are tested.

Standard drug combinations that we test for SEF chemo are:

carboplatin alone
carboplatin + sodium phenylbutyrate (we find the most success with this combination)
carboplatin + metformin
carboplatin + sodium dichloroacetate
carboplatin + gemcitabine

Please note that the actual cancer cell kill in the body is significantly higher than what a CS/CR assay predicts. The reason is that SEF chemo is a chemo-immunotherapy, but CS/CR assays don’t measure cell kill due to anti-cancer immunity. They only measure the direct kill from the drug or drug combination.




At Medicor, we have administered 595 cycles of SEF chemo as of March 2017. Standard carboplatin dosing is AUC8 (total) per 4 weeks. This is more chemo than the typical dosing given in a hospital setting, for example for ovarian cancer. Minimum carboplatin dosing is AUC6.4 (total) per 4 weeks. Patient data has all been carefully recorded, and now we have begun the process of analyzing the data. Preliminary findings are extremely favourable, confirming the high safety level of this therapy. Out of all 595 cycles, the following rates of serious complications attributed directly to the therapy have been noted:

MI (heart attack): 0%

CVA (stroke): 0.2%

febrile neutropenia (fever with low white cell count, requiring hospital admission for intravenous antibiotics): 0%*

tumour lysis syndrome: 0% (we have treated lymphoma, not leukemia)

vomiting requiring hospital admission: 0.5%**

life-threatening carboplatin allergy: 0.2%

death: 0%

*includes treatment of patients with active infections such as abscess, pneumonia and rectovesical fistula, which is not possible with regular chemotherapy

**not chemo drug side effect, caused by bowel blockage due to tumour inflammation after chemo, where there was an existing tumour pressing on the bowel


We are currently working on detailed response data.


We have treated the following cancer types so far: anal (squamous cell), bladder (transitional cell), brain (glioblastoma), breast (ductal adenocarcinoma), cervix, colon (adenocarcinoma), esophageal (adenocarcinoma), Fallopian tube (adenocarcinoma), lung (non-small cell), lung (small cell), lymphoma (non-Hodgkin’s), melanoma, oropharyngeal (squamous cell), ovarian (adneocarcinoma), pancreas (adenocarcioma), prostate (adenocarcinoma), sarcoma (clear cell), sarcoma (lipo), small bowel (adenocarinoma), thyroid (papillary). Cancer reduction has been successfully achieved in all of these tumour types.

The most obvious and dramatic results have been achieved in breast cancer patients with large visible tumours (especially those growing through the skin), who have not had prior chemotherapy. In these patients there is no difficulty in determining response because it is visually evident. The limitations of CT scans in measuring the response to immunotherapy (like SEF chemo) are avoided. We have treated 4 such patients, with rapid responses in all of them. This includes estrogen receptor positive breast cancer and “triple negative” breast cancer (estrogen / progesterone / HER2 negative). A sample case is presented below. Note that this is not a rare example of what can be achieved, but this represents the typical response of the small group of 4 chemo-naive patients.


WARNING: Graphic images are presented of a tumour growing outside the body. Please scroll down only if you are comfortable viewing such images.


Case of triple negative breast cancer

This 60 year old female developed a breast mass which was confirmed to be triple negative infiltrating ductal carcinoma by core needle biopsy. The patient saw a surgeon who determined the tumour was attached to the pectoralis muscle. Pre-operative cytotoxic chemotherapy was recommended to reduce the mass, in order to allow a successful operation without partial removal of the muscle. The patient educated herself about the risks and benefits of cytotoxic chemotherapy and declined to take this therapy. Over the course of approximately 1.5 years the patient tried various natural therapies and non-toxic off-label allopathic drugs (including DCA). Finally she decided to try SEF chemotherapy, since substantial reduction of the mass was not achieved with gentler therapies. The photos below show the progression of the therapy from pre-SEF to completion of 9 cycles of carboplatin AUC4 (2 week cycle) with mesna as a cytoprotective.


Before SEF chemo (after failure of natural and gentle drug therapies):


Mass is bleeding and oozing from dead cancer cells on the surface and infection.


After 2 cycles of SEF chemo:


Fragments of dead tumour have fallen away, residual tumour is drying up.


After 3 cycles of SEF chemo:


Most of the tumour mass has fallen off, small amount of residual tumour in the center. Bleeding has almost stopped.


After 9 cycles of SEF chemo:


The massive defect left by the dead tumour has healed with scar tissue (pink). A surgeon was consulted who confirmed no detectable live tumour remained on the right chest. The patient was given the option of having surgery to clean up the scar tissue. The patient experienced almost zero side effects during SEF chemotherapy. The most serious side effects were:

a) reduction of absolute neutrophil conunt to 0.8 after cycle #3 (corrected with a small mesna dose adjustment)

b) reduction of platelet count to 66 after cycle #6  (corrected with a further mesna dose adjustment).

Blood cell counts 3 weeks after cycle 9 were: HB=118, ANC=3.5, PLT=142


Further case reports to follow.



For details about the treatment schedule including drug timings, please see SEF Chemo Patient Instructions

Call Medicor at 416-227-0037
Email Dr. Khan:
Email the SEF chemo team:

Updated: Apr 1, 2017